drugset / Trial / NCT01176903

Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration

NCT01176903

Phase 1/2 Completed 65 enrolled Chiesi Farmaceutici S.p.A.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and the efficacy of Glycopyrrolate as pMDI after single and repeated administration.

Timeline

Start
2010-08
Primary completion
2010-11
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrrolate Small molecule 12.5 ug Inhaled
Subject Glycopyrrolate Small molecule 25 ug Inhaled
Subject Glycopyrrolate Small molecule 50 ug Inhaled
Subject Glycopyrrolate Small molecule 100 ug Inhaled
Subject Glycopyrrolate Small molecule 200 ug Inhaled
Comparator Tiotropium Other / unclassified 18 ug Inhaled